vs
Side-by-side financial comparison of Boston Scientific (BSX) and PAN AMERICAN SILVER CORP (PAAS). Click either name above to swap in a different company.
Boston Scientific is the larger business by last-quarter revenue ($5.2B vs $2.8B, roughly 1.9× PAN AMERICAN SILVER CORP).
Boston Scientific Corporation (BSC) is an American biotechnology and biomedical engineering firm and multinational manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.
Pan American Silver Corporation is a mining company based in Canada with operations in Latin America. The company has mines and other projects in Mexico, Peru, Bolivia, and Argentina.
BSX vs PAAS — Head-to-Head
Income Statement — Q1 FY2026 vs Q3 FY2022
| Metric | | |
|---|---|---|
| Revenue | $5.2B | $2.8B |
| Net Profit | $1.3B | — |
| Gross Margin | 69.5% | 27.0% |
| Operating Margin | — | — |
| Net Margin | 25.7% | — |
| Revenue YoY | 11.6% | — |
| Net Profit YoY | — | — |
| EPS (diluted) | $0.90 | $-1.05 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $5.2B | — | ||
| Q4 25 | $5.3B | — | ||
| Q3 25 | $5.1B | — | ||
| Q2 25 | $5.1B | — | ||
| Q1 25 | $4.7B | — | ||
| Q4 24 | $4.6B | — | ||
| Q3 24 | $4.2B | — | ||
| Q2 24 | $4.1B | — |
| Q1 26 | $1.3B | — | ||
| Q4 25 | $670.0M | — | ||
| Q3 25 | $755.0M | — | ||
| Q2 25 | $795.0M | — | ||
| Q1 25 | $672.0M | — | ||
| Q4 24 | $563.0M | — | ||
| Q3 24 | $468.0M | — | ||
| Q2 24 | $322.0M | — |
| Q1 26 | 69.5% | — | ||
| Q4 25 | 69.6% | — | ||
| Q3 25 | 69.9% | — | ||
| Q2 25 | 67.7% | — | ||
| Q1 25 | 68.8% | — | ||
| Q4 24 | 67.8% | — | ||
| Q3 24 | 68.8% | — | ||
| Q2 24 | 69.2% | — |
| Q1 26 | — | — | ||
| Q4 25 | 15.6% | — | ||
| Q3 25 | 20.7% | — | ||
| Q2 25 | 16.2% | — | ||
| Q1 25 | 19.8% | — | ||
| Q4 24 | 14.8% | — | ||
| Q3 24 | 17.4% | — | ||
| Q2 24 | 12.6% | — |
| Q1 26 | 25.7% | — | ||
| Q4 25 | 12.7% | — | ||
| Q3 25 | 14.9% | — | ||
| Q2 25 | 15.7% | — | ||
| Q1 25 | 14.4% | — | ||
| Q4 24 | 12.3% | — | ||
| Q3 24 | 11.1% | — | ||
| Q2 24 | 7.8% | — |
| Q1 26 | $0.90 | — | ||
| Q4 25 | $0.45 | — | ||
| Q3 25 | $0.51 | — | ||
| Q2 25 | $0.53 | — | ||
| Q1 25 | $0.45 | — | ||
| Q4 24 | $0.38 | — | ||
| Q3 24 | $0.32 | — | ||
| Q2 24 | $0.22 | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BSX
| MedSurg | $1.7B | 33% |
| EMEA | $932.0M | 18% |
| APAC | $803.0M | 15% |
| Endoscopy | $736.0M | 14% |
| Urology | $646.0M | 12% |
| Neuromodulation | $318.0M | 6% |
PAAS
Segment breakdown not available.
